Literature DB >> 9159739

Mitochondrial respiratory chain function in multiple system atrophy.

M Gu1, M T Gash, J M Cooper, G K Wenning, S E Daniel, N P Quinn, C D Marsden, A H Schapira.   

Abstract

Multiple system atrophy (MSA) is a clinico-pathological entity distinct from idiopathic Parkinson's disease (PD) that is responsible for 5-10% of cases of parkinsonism. Degeneration of nigral neurones is a feature of both diseases. A specific deficiency of mitochondrial complex I activity has been found in PD substantia nigra. We have analysed mitochondrial function in substantia nigra and platelets from MSA patients to identify any respiratory chain defect in this disorder and to determine its tissue specificity. As our MSA patients had been on L-DOPA, we also sought to establish whether this treatment could cause the complex I defect as seen in PD. We found no significant difference in respiratory chain activity corrected for mitochondrial mass between control and MSA patients in either of the tissues studied. These results provide a biochemical dimension to the differences between MSA and idiopathic PD. In addition, the fact that L-DOPA failed to induce a complex I defect in MSA substantia nigra suggests that this treatment is unlikely to cause the complex I deficiency in PD, without additional factors that may operate in PD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159739     DOI: 10.1002/mds.870120323

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

Review 1.  The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.

Authors:  D J Surmeier; J N Guzman; J Sanchez-Padilla; P T Schumacker
Journal:  Neuroscience       Date:  2011-08-25       Impact factor: 3.590

Review 2.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

3.  PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration.

Authors:  Yanbo Chen; Jianwen Deng; Peng Wang; Mengxue Yang; Xiaoping Chen; Li Zhu; Jianghong Liu; Bingwei Lu; Yan Shen; Kazuo Fushimi; Qi Xu; Jane Y Wu
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

4.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.

Authors:  J Zhang; G Perry; M A Smith; D Robertson; S J Olson; D G Graham; T J Montine
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 5.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

Review 6.  Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.

Authors:  Latha Devi; Hindupur K Anandatheerthavarada
Journal:  Biochim Biophys Acta       Date:  2009-07-18

7.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

Review 8.  Mouse models of Parkinson's disease associated with mitochondrial dysfunction.

Authors:  Alicia M Pickrell; Milena Pinto; Carlos T Moraes
Journal:  Mol Cell Neurosci       Date:  2012-08-11       Impact factor: 4.314

Review 9.  Calcium homeostasis, selective vulnerability and Parkinson's disease.

Authors:  C Savio Chan; Tracy S Gertler; D James Surmeier
Journal:  Trends Neurosci       Date:  2009-03-21       Impact factor: 13.837

Review 10.  Mitochondrial dysfunction in neurodegenerative diseases.

Authors:  Anthony H V Schapira
Journal:  Neurochem Res       Date:  2008-11-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.